[{"NetIncomeLoss_1_Q1_USD":-1769011.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q1_USD":138467720.0,"IncreaseDecreaseInPrepaidExpensesOther_1_Q1_USD":-50129.0,"AssetsCurrent_0_Q1_USD":935640.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_1_Q1_USD":0.0,"AccruedLiabilitiesCurrent_0_Q1_USD":1652522.0,"CommitmentsAndContingencies_0_Q1_USD":null,"GeneralAndAdministrativeExpense_1_Q1_USD":1779993.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"GainLossOnInvestments_1_Q1_USD":10982.0,"Liabilities_0_Q1_USD":7031849.0,"Cash_0_Q1_USD":682010.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":116827.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_1_Q1_USD":0.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q1_USD":0.0,"AssetsHeldInTrustNoncurrent_0_Q1_USD":149563934.0,"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0_Q1_USD":0.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":1264015.0,"DueToRelatedPartiesCurrent_0_Q1_USD":30000.0,"PrepaidExpenseCurrent_0_Q1_USD":253630.0,"UnrecognizedTaxBenefits_0_Q1_USD":0.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"PreferredStockSharesIssued_0_Q1_shares":0.0,"CashEquivalentsAtCarryingValue_0_Q1_USD":0.0,"AdditionalPaidInCapital_0_Q1_USD":7291565.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":682010.0,"AccountsPayableCurrent_0_Q1_USD":116827.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1_Q1_USD":-319022.0,"LiabilitiesCurrent_0_Q1_USD":1799349.0,"NetAssetValuePerShare_0_Q1_USD":1.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-319022.0,"IncreaseDecreaseInAccountsPayableRelatedParties_1_Q1_USD":30000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-2292094.0,"StockholdersEquity_0_Q1_USD":5000005.0,"PreferredStockSharesAuthorized_0_Q1_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":150499574.0,"PreferredStockValue_0_Q1_USD":0.0,"OperatingIncomeLoss_1_Q1_USD":-1779993.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"Assets_0_Q1_USD":150499574.0,"ReclassificationsOfTemporaryToPermanentEquity_1_Q1_USD":1769010.0,"Ticker":"NAUT","CIK":"1808805","name":"ARYA SCIENCES ACQUISITION CORP III","OfficialName":"Nautilus Biotechnolgy Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"491482396.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210513"}]